Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation

Published:2009-02 Issue:2 Volume:15 Page:231-241
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Bartelink Imke H.,Bredius Robert G.M.,Belitser Svetlana V.,Suttorp Marit M.,Bierings Marc,Knibbe Catherijne A.J.,Egeler Maarten,Lankester Arjan C.,Egberts Atoine C.G.,Zwaveling Juliette,Boelens Jaap Jan

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference53 articles.

1. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease;Bolinger;Bone Marrow Transplant,2000

2. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics;Slattery;Bone Marrow Transplant,1995

3. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies;Tran;Bone Marrow Transplant,2000

4. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages;Shaw;Bone Marrow Transplant,2004

5. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation. A report from the Societe Francaise de Greffe de Moelle;Michel;J Clin Oncol,1994

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. The Role of the Conditioning Regimen for Autologous and Ex Vivo Genetically Modified Hematopoietic Stem Cell-based Therapies: Recommendations from the ISCT Stem Cell Engineering Committee;Cytotherapy;2024-09

3. Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer;The Journal of Applied Laboratory Medicine;2024-02-09

4. Clinical Relevance of Therapeutic Drug Monitoring of Busulfan-Based Regimens in Adult Hematopoietic Stem Cell Transplant Patients;Archives of Pharmacy Practice;2024

5. Bayesian Statistical Methods in Stem Cell Transplantation and Cellular Therapy;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024